James Yan
Chief Tech/Sci/R&D Officer en ZAI LAB LIMITED .
Perfil
En la actualidad, James Yan es director de operaciones de investigación y desarrollo en Zai Lab Ltd. También es miembro de la Sociedad China de Toxicología. En su anterior carrera ocupó el puesto de Jefe de Evaluación de Seguridad de Medicamentos en Hutchison MediPharma Ltd. El Dr. Yan se doctoró en el Peking Union Medical College.
Cargos activos de James Yan
| Empresas | Cargo | Inicio |
|---|---|---|
| ZAI LAB LIMITED | Chief Tech/Sci/R&D Officer | 01/04/2020 |
| Chinese Society of Toxicology | Corporate Officer/Principal | - |
Antiguos cargos conocidos de James Yan.
| Empresas | Cargo | Fin |
|---|---|---|
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 01/01/2011 |
Formación de James Yan.
| Peking Union Medical College | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ZAI LAB LIMITED | Health Technology |
| Empresas privadas | 2 |
|---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
| Chinese Society of Toxicology |
- Bolsa de valores
- Insiders
- James Yan
